Russell Investments Group Ltd. Has $3.32 Million Stock Position in Hims & Hers Health, Inc. (NYSE:HIMS)

Russell Investments Group Ltd. cut its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 11.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 137,382 shares of the company's stock after selling 17,426 shares during the period. Russell Investments Group Ltd. owned approximately 0.06% of Hims & Hers Health worth $3,322,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Crewe Advisors LLC acquired a new stake in shares of Hims & Hers Health during the 4th quarter worth approximately $28,000. Raleigh Capital Management Inc. boosted its stake in Hims & Hers Health by 1,100.0% during the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after buying an additional 1,100 shares in the last quarter. Blume Capital Management Inc. increased its holdings in Hims & Hers Health by 100.0% in the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after buying an additional 600 shares during the period. Smartleaf Asset Management LLC raised its stake in shares of Hims & Hers Health by 4,415.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock valued at $36,000 after buying an additional 1,413 shares in the last quarter. Finally, Summit Securities Group LLC acquired a new position in shares of Hims & Hers Health in the 4th quarter valued at $38,000. Institutional investors and hedge funds own 63.52% of the company's stock.

Hims & Hers Health Stock Performance

HIMS traded up $0.29 during midday trading on Friday, reaching $27.24. 18,468,782 shares of the company were exchanged, compared to its average volume of 15,380,979. The stock has a market capitalization of $6.05 billion, a P/E ratio of 61.91 and a beta of 1.65. The stock's 50-day simple moving average is $37.26 and its 200 day simple moving average is $30.69. Hims & Hers Health, Inc. has a one year low of $11.20 and a one year high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings results on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.02. The company had revenue of $481.14 million during the quarter, compared to analyst estimates of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. On average, research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts recently issued reports on HIMS shares. Truist Financial dropped their price target on shares of Hims & Hers Health from $39.00 to $33.00 and set a "hold" rating for the company in a research report on Thursday, April 10th. Canaccord Genuity Group raised their target price on Hims & Hers Health from $38.00 to $68.00 and gave the stock a "buy" rating in a research report on Wednesday, February 19th. Piper Sandler upped their price target on Hims & Hers Health from $24.00 to $35.00 and gave the company a "neutral" rating in a research report on Tuesday, February 25th. BTIG Research initiated coverage on Hims & Hers Health in a research report on Tuesday, January 7th. They set a "buy" rating and a $35.00 price target on the stock. Finally, Morgan Stanley lowered shares of Hims & Hers Health from an "overweight" rating to an "equal weight" rating and increased their price objective for the stock from $42.00 to $60.00 in a report on Tuesday, February 18th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $38.25.

Insider Activity at Hims & Hers Health

In other news, CEO Andrew Dudum sold 36,460 shares of the stock in a transaction dated Wednesday, April 16th. The shares were sold at an average price of $28.04, for a total value of $1,022,338.40. Following the transaction, the chief executive officer now directly owns 92,103 shares of the company's stock, valued at $2,582,568.12. This represents a 28.36 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Soleil Boughton sold 54,153 shares of the business's stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $29.90, for a total value of $1,619,174.70. Following the sale, the insider now owns 165,650 shares of the company's stock, valued at approximately $4,952,935. This represents a 24.64 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 843,271 shares of company stock valued at $32,021,671. 17.71% of the stock is owned by insiders.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.